Overview

Dexmedetomidine vs. Remifentanil Undergoing Cataract Surgery in Geriatrics

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine is an α2-adrenergic receptor agonist used for its sympatholytic effect, providing sedation, analgesia, and cardiovascular stabilization in the perioperative period. Remifentanil is a µ opioid agonist with a rapid onset and short duration of action, which is degraded by plasma esterase in tissues. Investigators aimed to compare the effects of dexmedetomidine and remifentanil infusions on sedation quality, side effects, and surgeon's satisfaction in geriatric outpatients who underwent cataract surgery.
Phase:
N/A
Details
Lead Sponsor:
Selcuk University
Collaborator:
Hacettepe University
Treatments:
Dexmedetomidine
Remifentanil